Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571506 · ClinicalTrials.gov registry record · Phase 4
Effect of Thiazolidinedione Treatment Vascular Risk Markers
A Phase 4 study of Diabetes Mellitus, Type 2 and Vascular Diseases, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00571506 is a Phase 4 study of Diabetes Mellitus, Type 2 and Vascular Diseases that has completed, run by University of Arkansas. The registered enrollment target is 25 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00571506, a Phase 4 study of Diabetes Mellitus, Type 2 and Vascular Diseases, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of two diabetes medications, rosiglitazone and pioglitazone, on markers of vascular disease in subjects with type 2 diabetes.
Conditions Studied
Interventions
- DRUG Rosiglitazone
- DRUG Pioglitazone
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571506
The ClinicalTrials.gov registry entry for NCT00571506 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Rosiglitazone is the first listed.
NCT00571506 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00571506 about?
NCT00571506 is a clinical study titled "Effect of Thiazolidinedione Treatment Vascular Risk Markers". The purpose of this study is to examine the effects of two diabetes medications, rosiglitazone and pioglitazone, on markers of vascular disease in subjects with type 2 diabetes.
What is the current status of trial NCT00571506?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2004-05. Estimated completion is 2007-08.
What conditions does trial NCT00571506 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Vascular Diseases.
What interventions are being tested in trial NCT00571506?
The interventions under investigation include: Rosiglitazone (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00571506?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00571506 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.